JAMA psychiatrySep 2, 2026

Repeated Ketamine Treatments for Hard-to-Treat Bipolar Depression: A Randomized Clinical Trial

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 3, 2026

Abstract

The efficacy and safety of ketamine for bipolar depression remain largely unknown.

Antidepressant effects of intravenous ketamine have been established for major depressive disorder.
Limited data currently exists regarding its use in bipolar depression.
The specific impact of ketamine on symptoms of bipolar depression has not been thoroughly studied.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly Psychedelic Science Brief

You found one interesting study. We’ll send the next 7.

Get 7 new psychedelic science papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the psychedelic science brief

One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study

2 weeks ago7 studies

Psilocybin didn't create disorder in the brain — it created a different kind of order

3 weeks ago7 studies

Psilocybin worked for treatment-resistant depression in real Swiss clinics — not just controlled trials

4 weeks ago7 studies

Psilocybin beat placebo on depression scores in an NHS trial — by a lot

5 weeks ago7 studies

Psilocybin stays active in neurons long after it leaves the bloodstream — here's what that means

6 weeks ago7 studies

Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit

7 weeks ago7 studies

Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure

8 weeks ago7 studies

Psilocybin cut two specific brain chemicals in depressed patients — here's what that means

9 weeks ago7 studies

Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows

10 weeks ago7 studies

A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target

11 weeks ago7 studies

explore the archive

See more issues from the psychedelic science brief